EFFICACY AND SAFETY OF LOMUSTINE VERSUS FOTEMUSTINE AS FIRST AND SECOND LINE TREAMENT IN RELAPSED GLIOBLASTOMA PATIENTS

被引：0
|
作者：
Domenech, M. [1 ]
Fabregat, C. [2 ]
Hernandez, A. [1 ]
del Barco, S. [3 ]
Panciroli, C. [1 ]
Garcia-Illescas, D. [4 ,5 ]
Vieito, M. [4 ,5 ]
Vilarino, N. [2 ]
Mesia, C. [2 ]
Balana, C. [1 ]
机构：
[1] Catalan Inst Oncol Badalona, Badalona, Spain
[2] Catalan Inst Oncol Hosp, Lhospitalet De Llobregat, Spain
[3] Hosp Josep Trueta, Catalan Inst Oncol Girona, Girona, Spain
[4] Vall dHebron Univ Hosp, Barcelona, Spain
[5] Inst Oncol VHIO, Barcelona, Spain
来源：
NEURO-ONCOLOGY | 2021年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P14.58
引用
收藏
页码：49 / 49
页数：1
相关论文
共 50 条
  • [11] Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme
    Fazeny-Dörner, B
    Veitl, M
    Wenzel, C
    Piribauer, M
    Rössler, K
    Dieckmann, K
    Ungersböck, K
    Marosi, C
    [J]. ANTI-CANCER DRUGS, 2003, 14 (06) : 437 - 442
  • [12] TOXICITY AND EFFICACY OF LOMUSTINE PLUS BEVACIZUMAB IN RECURRENT GLIOBLASTOMA PATIENTS
    Jakobsen, Jan Nyrop
    Urup, Thomas
    Grunnet, Kirsten
    Christensen, Ib Jarle
    Villingshoj, Mette
    Poulsen, Hans Skovgaard
    [J]. NEURO-ONCOLOGY, 2017, 19 : 6 - 6
  • [13] Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience
    Scoccianti, Silvia
    Detti, Beatrice
    Sardaro, Angela
    Iannalfi, Alberto
    Meattini, Icro
    Leonulli, Barbara Grilli
    Borghesi, Simona
    Martinelli, Francesco
    Bordi, Lorenzo
    Ammannati, Franco
    Biti, Giampaolo
    [J]. ANTI-CANCER DRUGS, 2008, 19 (06) : 613 - 620
  • [14] Low-dose Fotemustine as Second-line Chemotherapy for Recurrent Glioblastoma Multiforme
    De Felice, Francesca
    Bulzonetti, Nadia
    Musio, Daniela
    D'Elia, Alessandro
    Salvati, Maurizio
    Tombolini, Vincenzo
    [J]. ANTICANCER RESEARCH, 2013, 33 (09) : 4013 - 4016
  • [15] Fotemustine as rescue therapy in recurrent or progressive glioblastoma after first-line temozolomide chemotherapy
    Lolli, Ivan
    Divella, Rosa
    Silvano, Giovanni
    Finamore, Simona
    Ercolino, Letizia
    Ronco, Michele
    Ciappetta, Pasqualino
    Troccoli, Giuseppe
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : 64 - 64
  • [16] Predictive factors of bevacizumab efficacy in relapsed glioblastoma patients
    Farina, Patrizia
    Labussiere, Marianne
    Lombardi, Giuseppe
    Di Stefano, Anna Luisa
    Gallego, Jaime
    Cheneau, Caroline
    Zagonel, VIttorina
    Sanson, Marc
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [17] Lomustine and Temozolomide in Combination with Radiotherapy New First-Line Treatment Option for Patients with MGMT Promoter methylated Glioblastoma
    Seidel, Clemens
    Kortmann, Rolf-Dieter
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 (09) : 855 - 856
  • [18] Efficacy of Second Line Therapy in Young Patients After Relapsed or Refractory Orbital Rhabdomyosarcoma
    Zloto, O.
    Boutroux, H.
    Brisse, H. J.
    Levy, C.
    Helfre, S.
    Orbach, D.
    [J]. PEDIATRIC BLOOD & CANCER, 2019, 66 : S402 - S403
  • [19] THE EFFICACY OF CEDIRANIB AS MONOTHERAPY AND IN COMBINATION WITH LOMUSTINE COMPARED TO LOMUSTINE ALONE IN PATIENTS WITH RECURRENT GLIOBLASTOMA: A PHASE III RANDOMIZED STUDY
    Batchelor, Tracy
    Mulholland, Paul
    Neyns, Bart
    Nabors, L. B.
    Campone, Mario
    Wick, Antje
    Mason, Warren
    Mikkelsen, Tom
    Phuphanich, Surasek
    Ashby, Lynn S.
    DeGroot, John F.
    Gattamancni, H. R.
    Cher, Lawrence M.
    Rosenthal, Mark A.
    Payer, Franz
    Xu, John
    Liu, Qi
    van den Bent, Martin
    [J]. NEURO-ONCOLOGY, 2010, 12 : 75 - 75
  • [20] A PHASE III RANDOMIZED STUDY COMPARING THE EFFICACY OF CEDIRANIB AS MONOTHERAPY, AND IN COMBINATION WITH LOMUSTINE, WITH LOMUSTINE ALONE IN RECURRENT GLIOBLASTOMA PATIENTS
    Batchelor, T.
    Mulholland, P.
    Neyns, B.
    Nabors, L. B.
    Campone, M.
    Wick, A.
    Mason, W.
    Xu, J.
    Liu, Q.
    van den Bent, M.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 4 - 4
12345